Journal article
The deferred promise of radical cure: pharmaceutical conjugations of malaria in the global health era
- Abstract:
-
This paper explores the changing political economy of malaria drug discovery by tracing the career over the last four decades of a single molecule, tafenoquine. First identified as a promising antimalarial by the US Army in the 1970s, tafenoquine has recently been approved by the Food and Drug Administration for the radical cure of vivax malaria – the first product to receive marketing authorization for this indication in more than 65 years. The new drug is the result of a collaboration betwe...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 295.8KB)
-
- Publisher copy:
- 10.1080/03085147.2018.1528075
Authors
Funding
Bibliographic Details
- Publisher:
- Taylor and Francis Publisher's website
- Journal:
- Economy and Society Journal website
- Volume:
- 47
- Issue:
- 4
- Pages:
- 547-571
- Publication date:
- 2018-11-27
- Acceptance date:
- 2018-09-12
- DOI:
- EISSN:
-
1469-5766
- ISSN:
-
0308-5147
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:918931
- UUID:
-
uuid:0b45bb5f-be7b-41bf-8146-9eed1ebd160a
- Local pid:
- pubs:918931
- Source identifiers:
-
918931
- Deposit date:
- 2018-09-12
Terms of use
- Copyright holder:
- Informa UK Limited, trading as Taylor and Francis Group
- Copyright date:
- 2018
- Rights statement:
- © 2018 Informa UK Limited, trading as Taylor and Francis Group
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Taylor and Francis at https://doi.org/10.1080/03085147.2018.1528075
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record